Ceftolozane-tazobactam for the treatment of ventilator-associated infections by colistin-resistant Pseudomonas aeruginosa;Ceftolozano-tazobactam en el tratamiento de infecciones respiratorias asociadas a ventilación mecánica por Pseudomonas aeruginosa resistente a colistina

Revista Espanola de Quimioterapia

Volumn 30, Issue 3, 2017, Pages 224-228

  Lerma, Francisco Álvarez ^a,b,c   Bermudez, Rosana Muñoz ^a   Grau, Santiago ^a,b   Arnillas, María Pilar Gracia ^a,b,c   Sorli, Luisa ^a,d   Recasens, Lluis ^a   García, Miquel Mico ^e  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Barcelona Biomedical Research Park   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

^e Laboratori de Referencia de Catalunya   (Spain)

Author keywords

Ceftolozane tazobactam; Colistin resistant pseudomonas aeruginosa; ICU; Ventilator associated respiratory infection

Indexed keywords

ACICLOVIR; AZITHROMYCIN; AZTREONAM; CEFTOLOZANE PLUS TAZOBACTAM; CEFTRIAXONE; COLISTIN; DOBUTAMINE; HEMOGLOBIN; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; NORADRENALIN; OSELTAMIVIR; VANCOMYCIN; ACUTE PHASE PROTEIN; ANTIINFECTIVE AGENT; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALCOHOLISM; ANASARCA; ANTIBIOTIC RESISTANCE; ARTICLE; ARTIFICIAL VENTILATION; ATRIAL FIBRILLATION; BACTERIUM ISOLATION; BLOOD CLOT; CARDIOGENIC SHOCK; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE CARDIOMYOPATHY; CORONARY CARE UNIT; DEATH; DEPRESSION; DEVICE INFECTION; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; GASTROSCOPY; GENERAL CONDITION IMPROVEMENT; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE NECROSIS; HEART VENTRICLE FUNCTION; HEMODYNAMIC INSTABILITY; HEMOGLOBIN BLOOD LEVEL; HERPES SIMPLEX; HUMAN; HYPERTENSION; HYPOTENSION; HYPOVOLEMIC SHOCK; INFLUENZA A; INTERMITTENT CLAUDICATION; INTUBATION; KIDNEY TUBULE NECROSIS; LUNG ABSCESS; MALE; MEDICAL HISTORY; MICROBIOLOGICAL EXAMINATION; MICTURITION DISORDER; MIDDLE AGED; NONHUMAN; OLIGOANURIA; OXYGEN DESATURATION; PEPTOCLOSTRIDIUM DIFFICILE; PERIPHERAL VASCULAR DISEASE; PHYSICAL DISEASE; PNEUMONIA; PSEUDOMEMBRANOUS COLITIS; PSEUDOMONAS AERUGINOSA; PULMONARY HYPERTENSION; RENAL REPLACEMENT THERAPY; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; REVASCULARIZATION; STOMACH ULCER; THERMODILUTION; THORAX RADIOGRAPHY; TRACHEOBRONCHITIS; TRACHEOSTOMY; TREATMENT DURATION; TREATMENT RESPONSE; VENTILATOR ASSOCIATED INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; ANALOGS AND DERIVATIVES; DRUG EFFECTS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PSEUDOMONAS INFECTION;

ACUTE-PHASE PROTEINS; AGED; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COLISTIN; DRUG RESISTANCE, BACTERIAL; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PENICILLANIC ACID; PNEUMONIA, VENTILATOR-ASSOCIATED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 85040075066     PISSN: 02143429     EISSN: 19889518     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Juan C, Zamorano L, Pérez JL, Ge Y, Oliver A; Spanish Group for the Study of Pseudomonas; Spanish Network for Research in Infectious Diseases. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother. 2010; 54:846-51.
2. Huntington JA, Sakoulas G, Umeh O, Cloutier DJ, Steenbergen JN, Bliss C, et al. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the AS-PECT-cUTI trial. J Antimicrob Chemother. 2016; 71:2014-21.
3. Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steen- bergen J. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: Results from a randomized, double-blind, phase 3 trial (ASPECT-cI-AI). Clin Infect Dis. 2015; 60:1462-71.
4. Zarkotou O, Pournaras S, Voulgari E, Chrysos G, Prekates A, Vout-sinas D, et al. Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: A matched case-control study. J Clin Microbiol. 2010;48:2271-74.
5. Kontopidou F, Plachouras D, Papadomichelakis E, Koukos G, Galani I, Poulakou G, et al. Colonization and infection by colistin-resistant gram-negative bacteria in a cohort of critically ill patients. Clin Microbiol Infect. 2011;17:9-11.
6. Samonis G, Korbila IP, Maraki S, Michailidou I, Vardakas KZ, Kofteridis D, et al. Trends of isolation of intrinsically resistant to colistin Enterobacteriaceae and association with colistin use in a tertiary hospital. Eur J Clin Microbiol Infect Dis. 2014; 33:1505-10.
7. Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother. 2012; 67: 1607-15.
8. Nakamura I, Sakamoto N, Ida Y, Imai R, Aoki K, Ando R, et al. Combination Therapy against polymicrobial infection, including by NDM-1-producing Enterobacteriaceae resistant to colistin. Antimicrob Agents Chemother. 2015; 59:5092-3.
9. European Medicines Agency (EMA). Ceftolozane-tazobactam Summary of Product Characteristics [Spanish Version]. Available at: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/003772/WC500194595.pdf (Last accessed, September 3, 2016).
10. Bremmer DN, Nicolau DP, Burcham P, Chunduri A, Shidham G, Bauer KA. Ceftolozane/Tazobactam pharmacokinetics in a critically ill adult receiving continuous renal replacement therapy. Pharmaco-therapy. 2016; 36:e30-e33.
11. Oliver WD, Heil EL, Gonzales JP, Mehrotra S, Robinett K, Saleeb P et al. Ceftolozane-tazobactam pharmacokinetics in a critically ill patient on continuous venovenous hemofiltration. Antimicrob Agents Chemother. 2015; 60:1899-901.
12. Gelfand MS, Cleveland KO. Ceftolozane/Tazobactam therapy of respiratory infections due to multidrug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2015; 61: 853-5.
13. Clinical Trials. Gov. Safety and efficacy study of ceftolozane/tazobactam to treat ventilated nosocomial pneumonia (MK-7625A-008) (ASPECT-NP). A prospective, randomized, double-blind, multicenter, phase 3 study to assess the safety and efficacy of intravenous ceftolozane/tazobactam compared with meropenem in adult patients with ventilated nosocomial pneumonia. Available at: https://clinicaltrials.gov/show/NCT02070757